Cat. No.: HY-B0078

Dacarbazine

(Synonyms: Imidazole Carboxamide)

15 Cited Publications

Customer Review

Based on 15 publication(s) in Google Scholar

Dacarbazine is a nonspecific antineoplastic (antineoplastic) alkylating agent. Dacarbazine inhibits T and B lymphocyte responses with IC₅₀ of 50 and 10 μg/mL, respectively. Dacarbazine can be used in the study of metastatic malignant melanoma.

For research use only. We do not sell to patients.

Purity: 99.96%
CAS No.: 4342-03-4
Formula: C₆H₁₀N₆O
Molecular Weight:182.18

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Dacarbazine Chemical Structure

CAS No.: 4342-03-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (15)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	>100 μM Compound: DTIC	Antiproliferative activity against human A375 cells after 48 hrs by SRB assay Antiproliferative activity against human A375 cells after 48 hrs by SRB assay	[PMID: 20056548]
A-375	IC₅₀	>100 μM Compound: DTIC, dacarbazine	Antiproliferative activity against human A375 cells after 48 hrs by SRB assay Antiproliferative activity against human A375 cells after 48 hrs by SRB assay	[PMID: 18477505]
A-375	IC₅₀	>500 μM Compound: dacarbazine	Cytotoxicity against human A375 cells after 48 hrs by MTT assay Cytotoxicity against human A375 cells after 48 hrs by MTT assay	[PMID: 22560315]
A549	IC₅₀	35 μg/mL Compound: Dacarbazine	Cytotoxicity against Homo sapiens (human) A549 cells assessed as cell viability by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells assessed as cell viability by MTT assay	10.1007/s00044-007-9031-x
B16-F1	IC₅₀	>100 μM Compound: DTIC	Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay	[PMID: 20056548]
B16-F1	IC₅₀	>100 μM Compound: DTIC, dacarbazine	Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay	[PMID: 18477505]
Fibroblast	IC₅₀	>100 μM Compound: DTIC	Cytotoxicity against human fibroblasts after 48 hrs by SRB assay Cytotoxicity against human fibroblasts after 48 hrs by SRB assay	[PMID: 20056548]
HeLa	GI₅₀	>50 μM Compound: DTIC	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 to 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 to 48 hrs by MTT assay	[PMID: 24986661]
MDA-MB-435	GI₅₀	84.33 μM Compound: Dacarbazine	Growth inhibition of human MDA-MB-435 cells measured after 24 to 72 hrs by SRB method Growth inhibition of human MDA-MB-435 cells measured after 24 to 72 hrs by SRB method	[PMID: 37163949]
OVCAR-3	IC₅₀	17.67 μM Compound: Dacarbazine	Cytotoxicity against human OVCAR3 cells after 6 days by MTT assay Cytotoxicity against human OVCAR3 cells after 6 days by MTT assay	[PMID: 21131205]
Raji	IC₅₀	128 μM Compound: DTIC	In vitro cytotoxicity against Raji cell line In vitro cytotoxicity against Raji cell line	[PMID: 7739008]
SK-MEL-2	IC₅₀	120 μM Compound: Dacarbazine	Cytotoxicity against human SK-MEL-2 cells after 6 days by MTT assay Cytotoxicity against human SK-MEL-2 cells after 6 days by MTT assay	[PMID: 21131205]
SK-MEL-28	GI₅₀	>100 μM Compound: Dacarbazine	Growth inhibition of human SK-MEL-28 cells measured after 24 to 72 hrs by SRB method Growth inhibition of human SK-MEL-28 cells measured after 24 to 72 hrs by SRB method	[PMID: 37163949]
UACC-62	IC₅₀	11.83 μM Compound: Dacarbazine	Cytotoxicity against human UACC62 cells after 6 days by MTT assay Cytotoxicity against human UACC62 cells after 6 days by MTT assay	[PMID: 21131205]
WM164	IC₅₀	>100 μM Compound: DTIC	Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay	[PMID: 17561392]
WM164	IC₅₀	>100 μM Compound: DTIC	Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay	[PMID: 20056548]

In Vitro

Dacarbazine (6.25-500 μg/mL 48 h) combines with hyperthermia-induced cytotoxicity of A375 and MNT-1 melanoma cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[5]

Cell Line:

A375, MNT-1
Concentration:

6.25, 12.5, 25, 50, 100, 200, 400, 500 μg/mL
Incubation Time:

24, 48, 72 h
Result:

Inhibited cell viability in a concentration-dependent manner.

Cell Cycle Analysis^[5]

Cell Line:

A375, MNT-1
Concentration:

5.5, 115 μg/mL
Incubation Time:

48 h
Result:

Decreased (9.3%) the percentage of A375 cells at the S phase and increased the number of cells at G2/M.
Decreased MNT-1 cells at G0/G1, increasing in cells at both S and G2/M phases.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 4342-03-4
Appearance Solid
Molecular Weight 182.18
Formula C₆H₁₀N₆O
Color White to yellow
SMILES

O=C(C1=C(/N=N/N(C)C)NC=N1)N
Synonyms

Imidazole Carboxamide
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (15)

All In Vivo Efficacy StudyHistological Imaging/StainingCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Nature

Tumour extracellular vesicles and particles induce liver metabolic dysfunction. [Abstract]

2023 Jun;618(7964):374-382. PMID: 37225988

Dacarbazine purchased from MedChemExpress. Usage Cited in: Nature. 2023 Jun;618(7964):374-382. [Abstract]

Dacarbazine (60 mg/kg; i.p.; every other day for 8 d) significantly reduced red blood cell (RBC), reticulocyte (RET), and hemoglobin (HGB) counts in PBS- or B16F10-CL-EVP-educated mice.
Nat Commun

Synthetic vectors for activating the driving axis of ferroptosis. [Abstract]

2024 Sep 10;15(1):7923. PMID: 39256387
Adv Sci (Weinh)

Patient-Derived Melanoma Immune-Tumoroids as a Platform for Precise High throughput Drug Screening. [Abstract]

2024 Dec;11(48):e2408707. PMID: 39475010

Dacarbazine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Dec;11(48):e2408707. [Abstract]

Dacarbazine (DTIC) (500 µM; 72 h) reduced the diameter and metabolic activity of MCTs except monoculture tumoroids, especially the triples and quadruples, resulting in a decrease of approximately 32% and 28% in relative diameter, respectively, and caused a high number of apoptotic cells to detach from the main structure.
Theranostics

Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. [Abstract]

2020 Jul 25;10(21):9477-9494. PMID: 32863940
J Nanobiotechnology

Combination of ferroptosis and pyroptosis dual induction by triptolide nano-MOFs for immunotherapy of Melanoma. [Abstract]

2023 Oct 19;21(1):383. PMID: 37858186

Dacarbazine purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2023 Oct 19;21(1):383. [Abstract]

Dacarbazine (DAC) (5 mg/kg; i.v.; once every three days for 3 times) significantly inhibited the growth of subcutaneous B16F10 melanoma xenografts in C57BL/6 mice.

Dacarbazine purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2023 Oct 19;21(1):383. [Abstract]

H&E staining of tumors in each group at the end of treatment. The results showed that Dacarbazine (DAC) (5 mg/kg; i.v.; once every three days for 3 times) caused significant cell necrosis and nucleopaenia in tumors of B16F10 tumor-bearing mice. Scale bar, 100 μm.
Carbohydr Polym

Chitosan/dextran-based organohydrogel delivers EZH2 inhibitor to epigenetically reprogram chemo/immuno-resistance in unresectable metastatic melanoma. [Abstract]

2024 Dec 15:346:122645. PMID: 39245506
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Cell Death Dis

MTCH2 regulates NRF2-mediated RRM1 expression to promote melanoma proliferation and dacarbazine insensitivity. [Abstract]

2025 Apr 9;16(1):268. PMID: 40204724

Dacarbazine purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 9;16(1):268. [Abstract]

Dacarbazine (20 mg/kg; i.p.; 20 d) reduced tumor growth rates and tumor sizes of melanoma xenograft mice.
Phytother Res

Isoalantolactone exerts anti-melanoma effects via inhibiting PI3K/AKT/mTOR and STAT3 signaling in cell and mouse models. [Abstract]

2024 Jun;38(6):2800-2817. PMID: 38526171
J Ethnopharmacol

Screening of anti-melanoma compounds from Morus alba L.: Sanggenon C promotes melanoma cell apoptosis by disrupting intracellular Ca2+ homeostasis. [Abstract]

2024 Apr 24:324:117759. PMID: 38219884
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Heliyon

Erzhi pills reverse PD-L1-mediated immunosuppression in melanoma microenvironment. [Abstract]

2024 Jan 18;10(3):e24988. PMID: 38317912
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
J Cancer Res Clin Oncol

Comprehensive analysis based on spatial domains identifies CD44 as a potential target of puerarin. [Abstract]

2025 Dec 17;152(1):12. PMID: 41405724
SSRN

2024 Mar 20.

Solvent & Solubility

In Vitro:

0.1 M HCl : 20 mg/mL (109.78 mM; ultrasonic and warming and heat to 60°C)

DMSO : 5 mg/mL (27.45 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.4891 mL

27.4454 mL

54.8908 mL

5 mM

1.0978 mL

5.4891 mL

10.9782 mL

10 mM

0.5489 mL

2.7445 mL

5.4891 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 2 mg/mL (10.98 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

Protocol 2

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 5 mg/mL (27.45 mM); Suspended solution; Need ultrasonic

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Serrone, L., et al., Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res, 2000. 19(1): p. 21-34. [Content Brief]

[2]. Al-Badr AA, et al. Dacarbazine. Profiles Drug Subst Excip Relat Methodol. 2016;41:323-77. [Content Brief]

[3]. Rojo JM, et al. Inhibition of T and B lymphoblastic response by mithramycin, dacarbazine, prospidium chloride and peptichemio. Chemotherapy. 1983;29(5):345-51. [Content Brief]

[4]. Erdmann S, et al. Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment. Sci Rep. 2019 Jan 10;9(1):30. [Content Brief]

[5]. Salvador D, et al. Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells. Int J Mol Sci. 2022 Mar 25;23(7):3586. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / 0.1 M HCl	1 mM	5.4891 mL	27.4454 mL	54.8908 mL	137.2269 mL
	5 mM	1.0978 mL	5.4891 mL	10.9782 mL	27.4454 mL
	10 mM	0.5489 mL	2.7445 mL	5.4891 mL	13.7227 mL
	15 mM	0.3659 mL	1.8297 mL	3.6594 mL	9.1485 mL
	20 mM	0.2745 mL	1.3723 mL	2.7445 mL	6.8613 mL
	25 mM	0.2196 mL	1.0978 mL	2.1956 mL	5.4891 mL
0.1 M HCl	30 mM	0.1830 mL	0.9148 mL	1.8297 mL	4.5742 mL
	40 mM	0.1372 mL	0.6861 mL	1.3723 mL	3.4307 mL
	50 mM	0.1098 mL	0.5489 mL	1.0978 mL	2.7445 mL
	60 mM	0.0915 mL	0.4574 mL	0.9148 mL	2.2871 mL
	80 mM	0.0686 mL	0.3431 mL	0.6861 mL	1.7153 mL
	100 mM	0.0549 mL	0.2745 mL	0.5489 mL	1.3723 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Dacarbazine

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Tumorigenesis-Related Compound Library

Pediatric Drug Library

Chemotherapy Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Dacarbazine

Biological Activity

Chemical Information

Publications (15)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Dacarbazine Related Classifications

Cat. No.: HY-B0078